Ortivus

Board/Management Information • Nov 1, 2024

Nomination committee in Ortivus AB (publ) ahead of the 2025 annual general meeting

The largest owners in Ortivus AB (publ) have appointed their representatives in the nomination committee ahead of the 2025 annual general meeting, which will be held on May 8, 2025.

The nomination committee for the 2025 annual general meeting consists of the following members:

• Anna-Carin Strandberg, chairman of the board, appointed by the 2024 annual general meeting
• Peter Edwall, appointed by the shareholder Ponderus Invest AB (represents 20.2% of the votes)
• Konstantin Papaxanthis (represents 11.5% of the votes)
• Pär-Ola Adolfsson (represents 3.4% of the votes)

Ortivus' guidelines for appointing the nomination committee were adopted at the annual general meeting on 8 May 2024 and are based on the guidelines in the Swedish Code of Corporate Governance. The nomination committee shall consist of four members. Of these, one shall be the chairman of the board and the other three shall be appointed by the three largest owners in the company as of September 30, 2024. To the extent that the shareholder questioned does not appoint a representative to the nomination committee, the question is passed on to the shareholder who is next in line in terms of size etc. The nomination committee will appoint the chairman of the nomination committee from within. The nomination committee shall, among other things, submit proposals for the number of board members, the composition of the board, chairman of the board, election of auditors, board and auditor fees and chairman of the annual general meeting. Those who wish to submit proposals or views to the election committee can do so in writing by letter to:

Ortivus AB (publ) The Nomination Committee Box 713 182 17 Danderyd

Contacts

For further information, please contact

Gustaf Nordenhök, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in realtime, MobiMed ePR, - an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, - a tool for navigation and case management, and MobiMed Life - a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

Attachments

Nomination committee in Ortivus AB (publ) ahead of the 2025 annual general meeting